Fig. 4: Drug-target MR estimates of GIPR and GLP1R agonism on alcohol misuse classifications comparing high-risk drinking to other drinking patterns. | Molecular Psychiatry

Fig. 4: Drug-target MR estimates of GIPR and GLP1R agonism on alcohol misuse classifications comparing high-risk drinking to other drinking patterns.

From: Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study

Fig. 4

This figure presents MR estimates assessing the effects of GIPR, GLP1R, and combined GIPR/GLP1R agonism on high-risk drinking behaviors compared to other drinking patterns, including low risk drinking (4v1), Internalizing alcohol use (4v2), and heavy drinking (4v3). Results are displayed separately for genetically proxied reductions in BMI (left) and HbA1c levels (right), reflecting distinct physiological mechanisms of these agonists. Odds ratios (OR) and 95% confidence intervals (CI) are plotted for both primary and replication datasets. Independent replication data sources are described in the Methods and Table 1. GIPR glucose-dependent insulinotropic polypeptide receptor, GLP1R glucagon-like peptide-1 receptor, BMI body mass index, HbA1c glycated hemoglobin, CI confidence interval.

Back to article page